LVTX
Income statement / Annual
Last year (2024), LAVA Therapeutics N.V.'s total revenue was $11.98 M,
an increase of 77.01% from the previous year.
In 2024, LAVA Therapeutics N.V.'s net income was -$25.11 M.
See LAVA Therapeutics N.V.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$11.98 M |
$6.77 M |
$19.39 M |
$5.35 M |
$3.75 M |
$0.00 |
| Cost of Revenue |
$467,000.00
|
$3.48 M
|
$0.00
|
$0.00
|
$15.70 M
|
$8.35 M
|
| Gross Profit |
$11.52 M
|
$3.29 M
|
$19.39 M
|
$5.35 M
|
-$11.95 M
|
-$8.35 M
|
| Gross Profit Ratio |
0.96
|
0.49
|
1
|
1
|
-3.19
|
0
|
| Research and Development Expenses |
$28.45 M
|
$33.81 M
|
$40.11 M
|
$36.95 M
|
$15.70 M
|
$8.35 M
|
| General & Administrative Expenses |
$13.23 M
|
$12.73 M
|
$14.12 M
|
$12.02 M
|
$2.72 M
|
$1.24 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.23 M
|
$12.73 M
|
$14.12 M
|
$12.02 M
|
$2.72 M
|
$1.24 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$41.68 M
|
$46.54 M
|
$51.31 M
|
$46.92 M
|
$3.59 M
|
$1.25 M
|
| Cost And Expenses |
$41.68 M
|
$50.02 M
|
$51.31 M
|
$46.92 M
|
$19.29 M
|
$9.60 M
|
| Interest Income |
$3.76 M
|
$2.97 M
|
$257,000.00
|
$625,000.00
|
$342,000.00
|
$86,000.00
|
| Interest Expense |
$515,000.00
|
$0.00
|
$0.00
|
$625,000.00
|
$342,000.00
|
$0.00
|
| Depreciation & Amortization |
$467,000.00
|
$1.28 M
|
$504,000.00
|
$331,000.00
|
$213,000.00
|
$99,000.00
|
| EBITDA |
-$23.50 M |
-$40.42 M |
-$30.88 M |
-$41.02 M |
-$14.65 M |
-$9.48 M |
| EBITDA Ratio |
-1.96
|
-5.97
|
-1.59
|
-7.67
|
-3.91
|
0
|
| Operating Income Ratio |
-2.48
|
-6.39
|
-1.8
|
-8.15
|
-3.92
|
0
|
| Total Other Income/Expenses Net |
$5.21 M
|
$1.56 M
|
$3.18 M
|
$1.42 M
|
-$1.21 M
|
-$104,000.00
|
| Income Before Tax |
-$24.48 M
|
-$41.70 M
|
-$31.66 M
|
-$42.20 M
|
-$15.88 M
|
-$9.69 M
|
| Income Before Tax Ratio |
-2.04
|
-6.16
|
-1.63
|
-7.89
|
-4.24
|
0
|
| Income Tax Expense |
$630,000.00
|
$279,000.00
|
$249,000.00
|
$157,000.00
|
$43,000.00
|
$0.00
|
| Net Income |
-$25.11 M
|
-$41.97 M
|
-$31.91 M
|
-$42.36 M
|
-$15.93 M
|
-$9.69 M
|
| Net Income Ratio |
-2.1
|
-6.2
|
-1.65
|
-7.92
|
-4.25
|
0
|
| EPS |
-0.94 |
-1.57 |
-1.23 |
-2.14 |
-39.9 |
-21.65 |
| EPS Diluted |
-0.94 |
-1.57 |
-1.23 |
-2.14 |
-39.9 |
-21.65 |
| Weighted Average Shares Out |
$26.83 M
|
$26.73 M
|
$25.92 M
|
$19.76 M
|
$25.35 M
|
$18.41 M
|
| Weighted Average Shares Out Diluted |
$26.83 M
|
$26.73 M
|
$25.92 M
|
$19.76 M
|
$25.35 M
|
$18.41 M
|
| Link |
|
|
|
|
|
|
